4.4 Article

Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis

Journal

THORACIC CANCER
Volume 13, Issue 12, Pages 1795-1805

Publisher

WILEY
DOI: 10.1111/1759-7714.14458

Keywords

circ_0001273; esophageal cancer; miR-622

Funding

  1. 2020 Maoming Science and Technology Special Fund Plan [2020S003]
  2. 2021 Guangdong Science and Technology Innovation Strategy Special Fund Project [2021S006]

Ask authors/readers for more resources

The study reveals that circ_0001273 is upregulated in esophageal cancer and contributes to its progression through modulating the miR-622/SLC1A5 signaling axis.
Background Esophageal cancer is a relatively rare cancer. However, its death rate is not to be taken lightly. Accumulating evidence indicates circular RNA (circRNA) is implicated in cancer development. The objective of this study was to unveil the role of circ_0001273 in esophageal cancer (EC). Methods For expression analysis of circ_0001273, miR-622 and solute carrier family 1 member 5 (SLC1A5), quantitative real-time PCR (qPCR) and Western blot were conducted. Cell proliferation was evaluated by cell counting kit-8 (CCK-8), EdU and colony formation assays. Cell apoptosis and cell migration were investigated using flow cytometry assay and wound healing assay. Glutamine metabolism was assessed by glutamine consumption and glutamate production using matched kits. The predicted binding relationship between miR-622 and circ_0001273 or SLC1A5 was validated by dual-luciferase reporter assay. An in vivo xenograft model was established to determine the role of circ_0001273 on tumor growth. Results Circ_0001273 was upregulated in EC tumor tissues and cells. Knockdown of circ_0001273 repressed EC cell proliferation, migration, epithelial-mesenchymal transition (EMT) and glutamine metabolism. Circ_0001273 knockdown also blocked tumor development in animal models. MiR-622 was targeted by circ_0001273, and its inhibition reversed the functional effects of circ_0001273 knockdown. SLC1A5 was a target gene of miR-622, and circ_0001273 targeted miR-622 to positively regulate SLC1A5 expression. The inhibitory effects of miR-622 enrichment on EC cell proliferation, migration, EMT and glutamine metabolism were recovered by SLC1A5 overexpression. Conclusion Circ_0001273 high expression contributed to EC progression via modulating the miR-622/SLC1A5 signaling axis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
Article Oncology

IgG4-related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non-small cell lung cancer: A case report

Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana

Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.

THORACIC CANCER (2024)

Article Oncology

Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants

Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda

Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.

THORACIC CANCER (2024)

Review Oncology

Advances in new targets for immunotherapy of small cell lung cancer

Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu

Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.

THORACIC CANCER (2024)

Article Oncology

A case of a shrunken multilocular mediastinal cyst that developed into thymic carcinoma with lung metastases 13 years later

Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima

Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.

THORACIC CANCER (2024)